245 related articles for article (PubMed ID: 21387285)
1. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
[TBL] [Abstract][Full Text] [Related]
2. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.
Kitadai Y; Sasaki T; Kuwai T; Nakamura T; Bucana CD; Fidler IJ
Am J Pathol; 2006 Dec; 169(6):2054-65. PubMed ID: 17148668
[TBL] [Abstract][Full Text] [Related]
3. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma.
Kodama M; Kitadai Y; Sumida T; Ohnishi M; Ohara E; Tanaka M; Shinagawa K; Tanaka S; Yasui W; Chayama K
Cancer Sci; 2010 Sep; 101(9):1984-9. PubMed ID: 20624165
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
5. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
8. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
[TBL] [Abstract][Full Text] [Related]
9. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Kim SJ; Uehara H; Yazici S; Busby JE; Nakamura T; He J; Maya M; Logothetis C; Mathew P; Wang X; Do KA; Fan D; Fidler IJ
J Natl Cancer Inst; 2006 Jun; 98(11):783-93. PubMed ID: 16757703
[TBL] [Abstract][Full Text] [Related]
10. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma.
Apte SM; Fan D; Killion JJ; Fidler IJ
Clin Cancer Res; 2004 Feb; 10(3):897-908. PubMed ID: 14871965
[TBL] [Abstract][Full Text] [Related]
11. Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.
Onoyama M; Kitadai Y; Tanaka Y; Yuge R; Shinagawa K; Tanaka S; Yasui W; Chayama K
Neoplasia; 2013 Dec; 15(12):1391-9. PubMed ID: 24403861
[TBL] [Abstract][Full Text] [Related]
12. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Pietras K; Pahler J; Bergers G; Hanahan D
PLoS Med; 2008 Jan; 5(1):e19. PubMed ID: 18232728
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
McCarty MF; Somcio RJ; Stoeltzing O; Wey J; Fan F; Liu W; Bucana C; Ellis LM
J Clin Invest; 2007 Aug; 117(8):2114-22. PubMed ID: 17641778
[TBL] [Abstract][Full Text] [Related]
17. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Johnson FM; Krug LM; Tran HT; Shoaf S; Prieto VG; Tamboli P; Peeples B; Patel J; Glisson BS
Cancer; 2006 Jan; 106(2):366-74. PubMed ID: 16342249
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
Yokoi K; Thaker PH; Yazici S; Rebhun RR; Nam DH; He J; Kim SJ; Abbruzzese JL; Hamilton SR; Fidler IJ
Cancer Res; 2005 May; 65(9):3716-25. PubMed ID: 15867367
[TBL] [Abstract][Full Text] [Related]
20. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
